Previous 10 |
Kiromic BioPharma (“the Company”) (NASDAQ: KRBP) , a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology, announced today the submission of two investigation...
Kiromic BioPharma (KRBP): Q3 GAAP EPS of -$0.65.Cash and equivalents of $0.47MPress Release For further details see: Kiromic BioPharma reports Q3 results
- Provisional patent filing titled, “Mesothelin Isoform Binding Molecules and Uses Thereof” - Completed external validation of clinical samples of key Isoform Mesothelin targets - Completed Construction of Vivarium and Clean Room Facilities at t...
Kiromic BioPharma, Inc. (the “Company”), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology, today announced the closing of its initial public offering of 1,250...
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
NASDAQ Market:
Kiromic BioPharma Inc. Website:
Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial’s Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company...
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...